IFNA1 and acute lymphoblastic leukemia: Thus, preemptive IFN-α treatment may not completely overcome the poor prognostic significance of MRDco+ status of ALL, and patients with MRDsin+ may benefit more from preemptive IFN-α treatment after allo-HSCT.